JP Patent

JP7094591B2 — 前立腺がんを診断および処置するためのｐｓｍａ標的放射性医薬品

Assigned to Futurechem Co Ltd · Expires 2022-07-04 · 4y expired

What this patent protects

Patent listed against lutetium-lu-177-vipivotide-tetraxetan.

Drugs covered by this patent

Patent Metadata

Patent number
JP7094591B2
Jurisdiction
JP
Classification
—
Expires
2022-07-04
Drug substance claim
No
Drug product claim
No
Assignee
Futurechem Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.